drugset / Trial / NCT02935153

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

NCT02935153 ↗

Phase 1/2 Unknown 45 enrolled Southwest Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

The overall purpose of this study is to explore the therapeutic effect of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Malignant B-cell Derived Leukemia and Lymphoma.

Timeline

Start
2016-10
Primary completion
2019-10
Completion
2020-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-CD22-CAR-transduced T cells Cell therapy — —

Indications